Literature DB >> 32300839

Osteoporosis care after distal radius fracture reduces subsequent hip or spine fractures: a 4-year longitudinal study.

Y H Shin1, W K Hong2,3, J Kim2, H S Gong4.   

Abstract

We evaluated whether active osteoporosis care in patients experiencing their first distal radius fracture (DRF) reduces subsequent hip or spine fractures by comparing two cohorts. The incidence of subsequent fractures was significantly lower in the active care cohort than the other cohort in 4-year follow-up.
PURPOSE: Studies show that osteoporosis care in patients with osteoporotic fracture reduces subsequent fractures, but the impact of such active care in patients with distal radius fracture (DRF) has not been well studied. We evaluated how much osteoporosis care in patients experiencing their first DRF can reduce subsequent hip or spine fractures at 4-year follow-up.
METHODS: Active osteoporosis care by orthopedic surgeons for patients with DRF started from September 2009 at our institution, thus we had a unique opportunity to compare the two cohorts: pre-involvement (PreI) group (DRF before September 2009) and post-involvement (PostI) group (DRF from September 2009). We compared the two cohorts for subsequent hip or spine fracture incidence in the 4 years following DRF.
RESULTS: Overall, 1057 patients with a DRF (85% women; mean age, 70 years) were studied, of whom 205 patients were in PreI group and 852 in PostI group. Subsequent fractures occurred in 27 patients (2.6%), with a mean interval of 29 months after DRF. The incidence was significantly lower in the PostI group than in the PreI group (1.9% vs. 5.4%, p = 0.004), especially in hip fractures (0.4% vs. 2.9%, p = 0.002). The relative risk reduction was 65% for all subsequent fractures and 86% for hip fractures.
CONCLUSION: This study demonstrates that active osteoporosis care in patients with DRF significantly reduces subsequent fracture incidence even for the 4-year follow-up period. These findings add an evidence for the current proactive osteoporosis care programs such as fracture liaison services. LEVEL OF EVIDENCE: Therapeutic level III.

Entities:  

Keywords:  Distal radius fracture; Hip fracture; Osteoporosis care; Subsequent fracture

Mesh:

Year:  2020        PMID: 32300839     DOI: 10.1007/s00198-020-05410-3

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  6 in total

1.  Risk Factors of Frailty in Patients with Distal Radius Fractures.

Authors:  Jeong-Hyun Kang; Seok Woo Hong
Journal:  Geriatr Orthop Surg Rehabil       Date:  2022-04-14

2.  Ferric Ion Induction of Triggering Receptor Expressed in Myeloid Cells-2 Expression and PI3K/Akt Signaling Pathway in Preosteoclast Cells to Promote Osteoclast Differentiation.

Authors:  Lu-Lin Liu; Zi-Hou Cao; Chun-Lei He; Yan-Chun Zhong; Wu-Yang Liu; Peng Zhang; Fan Yang; You-Jia Xu
Journal:  Orthop Surg       Date:  2020-07-30       Impact factor: 2.071

3.  The Relationship between Dietary Patterns and Bone Mineral Density of 476 Middle-Aged and Aged People.

Authors:  Yuguang Zhao; Jinhui Li; Zhigang Yuan; Xin Li; Hanghai Gu; Chuanming Jiao; Zhong Zhang
Journal:  Iran J Public Health       Date:  2021-10       Impact factor: 1.429

4.  A Novel Osteoporosis Screening Protocol to Identify Orthopedic Surgery Patients for Preoperative Bone Health Optimization.

Authors:  Elliot Chang; Brian Nickel; Neil Binkley; James Bernatz; Diane Krueger; Alec Winzenried; Paul A Anderson
Journal:  Geriatr Orthop Surg Rehabil       Date:  2022-08-06

5.  The Characteristics of Women with Subsequent Distal Radius Fracture after Initial Distal Radius Fracture.

Authors:  Jongjin Lee; Jae Kwang Kim; Minyoung Oh; Young Ho Shin
Journal:  J Bone Metab       Date:  2021-05-31

Review 6.  The impact of fracture liaison services on subsequent fractures and mortality: a systematic literature review and meta-analysis.

Authors:  N Li; M Hiligsmann; A Boonen; M M van Oostwaard; R T A L de Bot; C E Wyers; S P G Bours; J P van den Bergh
Journal:  Osteoporos Int       Date:  2021-04-07       Impact factor: 4.507

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.